 |
|
|
| |
Doravirine [Merck New NNRTI MK-1439] Efficacy Exposure-Response Analysis at Week 48 and Implications1 and Doravirine Pharmacokinetics After Switching from Efavirenz Therapy in Healthy Volunteers2
|
| |
| |
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy May 26, 2015
1Ka Lai Yeea, Xia Xua, Hedy Tepplera
2Rosa I Sancheza, Patrice Augerb, Rachael Liua, Li Fana, Ilias Triantafylloua, Charles Tomekb, Mike Di Spiritob, Marian Iwamotoa, Sauzanne Khalilieha
aMerck & Co., Inc., Kenilworth, NJ
bCelerion, Lincoln, NE, USA
|
| |
|
|
|
|
|
